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Aim. The creation of genetically engineered fusion protein SPA-BAPmut and its application as a secondary
immunoreagent in immunoassays. Methods. Gene cloning, PCR, electrophoresis, DNA sequencing, bacteria
cells culturing, protein expression and purification, ELISA, Western-blotting were used. Results. The DNA
sequences encoding Staphylococcus aureus protein A (SPA) and bacterial alkaline phosphatase with enhanced
catalytic activity (BAPmut) were used for construction of gene encoding fusion protein SPA-BAPmut that was
expressed in the high-productive Escherichia coli system and obtained in a soluble form. Cultivation conditions to
provide a high-level expression of SPA-ÂAPmut (> 1 g/l) were determined. The target protein was obtained with
purity more than 95 % using ²ÌÀÕ method. SPA-ÂAPmut is thermostable, and both parts of fusion protein (SPA
and BAPmut) retain their IgG binding and alkaline phosphatase activity for a long time. SPA-BAPmut was used as
a substitute of secondary an- tibodies in immunoassays. As little as 5 ng of the antigen could be detected in Western
blotting and 1g/ml of IgG in ELISA.Conclusions. The possibility of using SPA-ÂAPmut as universal secondary
immunoreagent for different types of immunoassays was shown.
Keywords: protein A, bacterial alkaline phosphatase, fusion protein, immunoassays.
Introduction. Staphylococcus aureus protein A (SPA)
consists of five immunoglobulin-binding domains (E,
D, A, B, C), each of them being capable of specific
interaction with Fc-fragments of IgG of different
animal species and humans [1]. Therefore, SPA is
widely used in affinity chromatography to create
sorbents for purification of antibodies or separation of
blood of patients with autoimmune diseases from
autoantibodies and circulating immune complexes [2,
3]. Another promising approach in SPA application is
diagnostics. The SPA conjugates with alkaline
phosphatase, horseradish peroxidase and stained iodine
are used in immunological tests. This conjugation is
usually conducted chemically. However chemical
conjugation has a number of disadvantages: 1) a great
number of required purified components; 2) high
heterogeneity of the final product; 3) necessity of
separating full-size conjugates from non-conjugated
components. In turn, the recombinant DNA technology
assures the elaboration of genetic constructions, which
can be used to obtain chimeric bifunctional proteins in
heterological systems, including Escherichia coli.
The bacterial alkaline phosphatase with enhanced
catalytic properties (BAPmut) was selected for fusion
with SPA. An increase in the BAPmut catalytic activity
was achieved via two aminoacid substitutes D153G and
D330N (substitution of aspartic acid for asparagine and
glycine in positions 153 and 330 respectively) [4].
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Materials and Methods. Construction and ex-
pression of SPA-BAPmut. DNA-sequence of SPA was
obtained via PCR-amplification from chromosomal
DNA of S. aureus, isolated using Genomic DNA
Purification Kit (Fermentas, Lithuania). A pair of
specific primers, introducing restriction sites NdeI and
NotI, was used to conduct PCR. The purified PCR
product (~880 b.p.) was hydrolyzed by respective
restrictases and cloned into plasmid vector pET-24a
(resulting plasmid – pETSPA) [5].
PCR was conducted using the following pair of
primers: sense SPA – NdeI:
5’-ATCATATGGCGCAACACGATGAAGCTCAAC-3’;
antisense SPÀ – NotI:
5’-ATGCGGC CGCTTCCT CTTTTGGTGC-3’.
Plasmid pCANTAB-ScFv-BAPmut and a pair of
primers, introducing restriction sites NotI and XhoI,
were used to obtain DNA sequences, encoding
BAPmut. The purified PCR product (~1360 b.p.) was
hydrolyzed by respective restrictases and subcloned in-
to plasmid vector pET-SPA. PCR was conducted using
the following pair of primers: sense BAPmut – NotI:
5’-ACGGGCGGCCGCTACACCAGAA-3’;
antisense BAPmut – XhoI:
5’CGGCGAGACCCCGACTTTGAGCTCACTA-3’.
For the expression of SPA-BAPmut, E. coli BL21
(DE3) cells were transformed by obtained plasmid
pET24-SPA-BAPmut. The Protein expression was in-
duced by the autoinduction protocol [6]. The locali-
zation and content of the target protein in the total
lysate of cells-producents were determined by electro-
phoretic separation of the soluble and insoluble frac-
tions of cell cytoplasm proteins.
The purification of SPA-BAPmut was performed by
Immobilized-metal affinity chromatography (IMAC)
in native conditions. 1 ml HiTrap chelating column
balanced with Ni2+ ions was connected to an FPLC
system (Pharmacia) , equilibrated with the buffer (100
mM tris-HCl (pH 8.0), 300 mM NaCl, 10 mM
imidazole) with the flow rate of 0.5 ml/min and a
fraction of soluble proteins of cytoplasm of E.coli cells
previously filtered through 0.45 µm- membrane PVDF
filter (Millipore, USA) was added . The column was
washed from non-specifically bound proteins by the
mentioned buffer until the recording pen got to the
baseline. SPA-BAPmut was eluted by the buffer – 100
mM tris-HCl (pH 8.0), 300 mM NaCl, 300 mM
imidazole. The purified protein was dialyzed against
the buffer, containing 100 mM tris-HCl (pH 9.5), 140
mM NaCl, 15 mM MgSO4. The homogeneity of the
purified protein was analyzed in 12% SDS-PAAG [7],
SPA-BAPmut concentration was determined using the
known value of A280 adsorption, calculated from this
sequence using Vector NTI software.
The application of SPA-BAPmut as a secondary im-
munoreagent. Antibody-dependent ELISA. rhIFN2b
(PharmBiotec Scientific Production Company,
Ukraine) in 50 mM Na-carbonate buffer (pH 9.5) in the
concentration of 10 µg/ml was added to the wells of
polystyrene plate for ELISA (Nunc, Denmark) and
incubated for 1 h at 37°C. After washing the wells with
PBST buffer, the affinity purified rabbit polyclonal
anti-rhIFNá2b antibodies in the concentration range of
100–0.1 µg/ml and SPA-BAPmut, 0.5 µg/ml, were
added. The obtained immune complexes were
visualized using p-nitrophenylphosphate, (pNPP,
Sigma, USA). After staining the reaction was
terminated by the introduction of 1 M NaOH and A405
adsorption value was measured using multichannel
photometer Multiscan MCC/340 (Titertek, USA).
Antigen-dependent ELISA. rhIFNá2b in 50 mM
Na-carbonate buffer (pH 9.5) in the concentration of
1–500 ng per well was added to the wells of polystyrene
plate for ELISA (Nunc) and incubated for 1 h at 37°C.
After washing the wells with PBS buffer which
contains 0.1% twin-20 (PBST), the affinity purified
rabbit polyclonal anti-rhIFNá2b antibodies [8] in the
concentration 1 µg/ml and SPA-BAPmut in the
concentration 0.5 µg/ml, were added.
Dot-blot analysis. Antigen rhIFNá2b in the amount
of 5–20 ng was applied to the nitrocellulose membrane
Hybond-C Extra (Amersham Biosciences, UK). After
blocking the sites of non-specific binding by buffer
PBS + 3 % milk (PBSM), the membrane with
immobilized proteins was incubated for 1 h with
purified rabbit polyclonal anti-rhIFNá2b antibodies in
the concentration of 1 µg/ml. Antigen rhExCD34 was
applied onto the membrane as a negative control [9].
The target protein was detected using SPA-BAPmut in
the concentration of 0.5 µg/ml. For visualization of
immune complexes Alkaline Phosphatase chromogen
substrate BCIP-T/NBT (Sigma) was used.
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The determination of the thermostability of the
fusion protein SPA-BAPmut. The aliquotes of the
purified SPA-BAPmut (1 mg/ml in the buffer of 0.1 M
tris-HCl (pH 9.5), 0.14 M NaCl, 15 mM MgSO4) were
incubated at the following temperatures: +4, +50, +70,
+85, +95, –20, –70°Ñ for 10 min. The enzymatic
activity of the alkaline phosphatase and IgG-binding
activity of protein A were determined in ELISA.
Results and Discussion. In addition to affinity
chromatography, the application of SPA, fused with the
marker molecule, is promising for the determination of
antibodies and specific antigens via specific antibodies.
While selecting the marker molecule , the following
parameters were taken into consideration: high
enzymatic activity, a wide spectrum of commercially
available substrates, considerable thermostability,
small size, possibility of the obtaining in bacteria, and
stability after conjugation with other proteins. The
selection was ended with alkaline phosphatase (AP),
widely used to elaborate immunoconjugates for
immunochemical methods. Mammalian alkaline
phosphatase (MAP) is remarkable for its high kcat value
(about 2000 s–1) and thermolability (Tm ~ 65°Ñ) [4]. The
immunoconjugates with MAP are usually obtained via
chemical conjugation [10]. Bacterial alkaline phospha-
tase (BAP) is less active compared to MAP, its kcat value
being 65–80 s–1, but it is more thermostable – Tm is ~
95°Ñ. The immunoconjugates with BAP can be
obtained by traditional chemical conjugation and in a
more convenient way, i.e. by gene engineering combi-
nation of BAP sequence and the sequence of the marker
molecule. High thermostability, the capability to
forming gene-engineered conjugation as well as the
possibility of efficient obtaining such conjugates in the
active form via bacterial expression make BAP a
promising alternative to MAP. Therefore, we preferred
BAP as a marker molecule with the increased catalytic
activity (BAPmut).
The comparative analysis of the structure of active
sites of MAP and BAP demonstrated aminoacid
substitutes, highly improving the catalytic activity of
the latter. For instance, the aminoacid substitutes
K328H/D330N increase the enzymatic activity of BAP
three-fold, D153H/K328Í, D153H/K328H/D330N –
eight-fold, D153H/D330N – up to 17-fold. However,
along with the enzymatic activity majority of the
mentioned mutations lead to considerable decrease in
the thermostability of the enzyme, which decreases the
value of the latter as a component of immunoreagents.
Mutations D330N/D153G were found, which increase
the catalytic activity of BAP by about 17–40 times
(depending on the incubation medium content) and do
not impact the enzyme thermostability [4]. BAP with
the abovementioned properties (aminoacid substitutes
D330N/D153G) was used to obtain SPA-BAPmut.
The interactive design of the chimeric protein was
conducted considering structural specificities of both
moieties of SPA-BAPmut and the topology of their
active sites. It was determined that optimal design of the
chimeric protein presupposes fusion of BAPmut with
C-terminus of SPA. This location secures the functional
properties of phosphatase, as C- terminus, participating
in the formation of the molecule active site, is not
involved. The abovementioned location of SPA relative
to the enzyme does not hinder the dimerization of a
phosphatase molecule, required for its functioning, and
increases the avidity of the formed immunoconjugate,
thus increasing its sensitivity (Fig. 1). At the same time
the location of the phosphatase on the N-terminus of the
fused partner is a reason of of the loss of functional
activity of the latter [11].
For large-scale production of SPA-BAPmut E. coli
cells, strain BL21 (DE3), were transformed by the
plasmid vector pET-24-SPA-BAPmut (Materials and
Methods). Expression of SPA-BAPmut was induced by
the autoinduction protocol [6]. The electrophoretic
analysis of the lysates of bacterial cells demonstrated
the band of expected molecular mass (~78 kDa)
(Fig. 2). The electrophoretic separation of soluble and
insoluble fractions of cytoplasm proteins showed that
SPA-BAPmut is synthesized in the soluble form, the
level of its accumulation is 37% of the total proteins of
E. coli cells (~ 0.96 g/l of the bacterial culture) at the
optic density A600 = 16.3. This value is almost 45 times
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XhoI
Fig. 1. The scheme of location of the elements of the expression
cassette of SPA-BAPmut in vector pET-24a(+)
higher than the yield of similar fusion protein SPA
APK328A, the obtaining of which is described [12].
The isolation of such conjugates requires com-
binations of the following methods: cells disruption by
sonication, centrifugation, ion-exchange chromatogra-
phy, gel-filtration, chromatography of hydrophobic
interactions, precipitation, affinity chromatography,
which, it should be noted, is the reason of the decrease
in the functional activity of the enzyme due to strict elu-
tion conditions. As SPA-BAPmut contains a geneti-
cally introduced His-tag sequence, it was purified using
IMAC under native conditions. To decrease non-
specific adsorption of contaminant proteins, which may
have significant impact on the purity of the final pro-
duct, the column was washed with the buffer, con-
taining 300 mM NaCl and 10 mM imidazole.
The elution of SPA-BAPmut was conducted with
the buffer, which contained 300 mM imidazole. The
mentioned conditions ensure obtaining SPA-BAPmut
with purity more than ~95% (Fig. 2). After the puri-
fication SPA-BAPmut was dialyzed against the buffer,
optimal for maintenance of the enzymatic activity of
alkaline phosphatase (Materials and Methods).
The data, summarized according to the results of
purification of SPA-BAPmut with using IMAC are
presented in the Table. It was demonstrated that this
method ensures obtaining SPA-BAPmut without
considerable loss of the product (yield ~91.6%) and its
functional activity.
The purified SPA-BAPmut was used as a secondary
antibody for the detection of antibodies (ELISA) and
antigenes (ELISA, dot-blotting). It was determined that
SPA-BAPmut reliably detects IgG in the concentration
of ~500 ng/ml and less than 15 ng/ml of antigen
(rhIFNá2b) (Fig. 3, 4). Besides, contrary to most of the
immunoenzymatic systems of detection with specific
secondary antibodies conjugated with a marker
molecule, the application of SPA-BAPmut allows
extending the range of primary antibodies (SPA
recognizes Fc-fragments of IgG of humans,
mice,rabbits, guinea pigs and bovine).
The thermostability of the fusion protein
SPA-BAPmut was also determined. For this reason the
aliquotes of SPA-BAPmut with the same concentration
were incubated at different temperatures (Materials and
Methods). SPA-BAPmut, isolated right prior to the
experiment, was used as control. As seen from the
diagram, presented in Fig. 5, SPA-BAPmut does not
lose its immunoglobulin-binding and phosphatase
activity during incubation at the temperature up to
70°Ñ; it also endures the impact of low temperatures
(Fig. 5). High thermostability of SPA-BAPmut is of
relevant diagnostic significance as usually
commercially available immunoconjugates are rather
thermolabile. It was shown that SPA-BAPmut
preserves its functional activity for at least 6 months if
stored in 50 % glycerol at 4°C in the corresponding
buffer.
Compared to the analogues, the suggested
immunoconjugates has higher sensitivity due to an
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1 2 3 4 5
Fig. 2. The expression of SPA-BAPmut in E. coli cells: 1 – molecular
weight markers (130, 100, 70, 55, 40, 35, 25, 15 and 10 kDa); 2 – total
lysate of producent cells with induced production of SPA-BAPmut; 3 –
fraction of insoluble proteins of the cell; 4 – fraction of soluble proteins
of the cell; 5 – SPA-BAPmut, isolated on metal affinity sorbent and
dialyzed against the buffer of 0.1 Ì tris-HCl, 0.14 Ì NaCl, 15 mM
MgSO
4
, ðÍ 9.5
Fraction
Volume,
ml
Total
amount of
protein, mg
Functional
activity
BAPmut, %
Soluble cytoplasm
proteins
10 6 100
After purification of
SPA-BAPmut on
Ni-NTA sepharose
5,7 5,6
Not
determined
After the replacement of
the buffer for elution
with the buffer optimal
for BAPmut
5,0 5,0 87
Purification of SPA-BAPmut on Ni-NTA sepharose
increase in the enzymatic activity of BAP. Besides,
contrary to traditional immunoreagents, created by che-
mical conjugation, the fusion protein SPA-BAPmut,
obtained in preparative amounts by high productive and
simple bacterial expression, allows for considerable
simplification of the laboratory and industrial produc-
tion of similar immunoreagents and reduction in the
cost of immunoconjugates.
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Ðåçþìå
Ìåòà. Ñòâîðåííÿ ãåííî-³íæåíåðíîãî çëèòîãî á³ëêà SPA-BAPmut
òà éîãî çàñòîñóâàííÿ ÿê âòîðèííîãî ³ìóíîðåàãåíòó â ³ìóíî-
ëîã³÷íèõ òåñòàõ. Ìåòîäè. Êëîíóâàííÿ ãåí³â, ÏËÐ, ñåêâåíóâàííÿ
ÄÍÊ, êóëüòèâóâàííÿ áàêòåð³é, åëåêòðîôîðåç, ñèíòåç ³ î÷èùåííÿ
á³ëê³â, ELISA, âåñòåðí-áëîò. Ðåçóëüòàòè. Ç âèêîðèñòàííÿì
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K+ +4 KT 70 20 +50 +70 +85 +95
OD405
0,0
0,5
1,5
2,0
2,5
3,0
3,5
Fig. 5. The impact of different temperatures on functional activity of
the fusion protein SPA-BAPmut: K+ – SPA-BAPmut immediately
after the isolation from E. coli cells; RT – room temperature (24 h); +4,
+50, +70, +85, +95, –70, –20°C (10 min)
IgG, µg/ml IgG ng/ml
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Fig. 3. The determination of
the minimal concentration
of IgG, detected using
SPA-BAPmut in ELISA
20 10 5 Ê
a b
À405
rhIFN2b, ng rhIFN2b, ng
1 4 16 64 2560
0,0
0,4
0,8
1,2
1,6
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Fig. 4. The determination of
antigen concentration
(rhIFNá2b), detected using
SPA-BAPmut in ELISA (a)
dot-blotting (b)
ïîñë³äîâíîâíîñòåé ÄÍÊ, ùî êîäóþòü á³ëîê À Staphylococcus
aureus (SPA) ³ áàêòåð³éíó ëóæíó ôîñôàòàçó ç ïîêðàùåíèìè êà-
òàë³òè÷íèìè âëàñòèâîñòÿìè (BAPmut), ñêîíñòðóéîâàíî ãåí çëè-
òîãî á³ëêà SPA-BAPmut òà çàáåçïå÷åíî éîãî ïðåïàðàòèâíå
îòðèìàííÿ ó ðîç÷èíí³é ôîðì³ âíàñë³äîê ñèíòåçó â êë³òèíàõ
Escherichia coli. Âèçíà÷åíî óìîâè ôåðìåíòàö³¿, çà ÿêèõ âèõ³ä
SPA-ÂAPmut ñòàíîâèòü ïðèáëèçíî 1 ã/ë êóëüòóðè E. coli. ²ç çà-
ñòîñóâàííÿì ìåòîäó ìåòàëîàô³ííî¿ õðîìàòîãðàô³¿ îäåðæàíî
ö³ëüîâèé á³ëîê ç ÷èñòîòîþ ïîíàä 95 %. SPA-ÂAPmut òåðìîñ-
òàá³ëüíèé, à îáèäâà éîãî êîìïîíåíòè (SPA ³ ÂAPmut) çáåð³ãàþòü
³ìóíîãëîáóë³íçâ’ÿçóâàëüíó ³ ôîñôàòàçíó àêòèâí³ñòü òðèâàëèé
÷àñ. SPA-BAPmut äîçâîëÿº âèÿâëÿòè ùîíàéìåíøå 5 íã àíòèãåíó
òà 1 ìêã/ìë àíòèò³ë. Âèñíîâêè. Ïîêàçàíî ìîæëèâ³ñòü âèêîðèñ-
òàííÿ SPA-ÂAPmut ÿê óí³âåðñàëüíîãî âòîðèííîãî ³ìóíîðåàãåíòó
â ³ìóíîõ³ì³÷íèõ òåñòàõ.
Êëþ÷îâ³ ñëîâà: á³ëîê À, áàêòåð³éíà ëóæíà ôîñôàòàçà, çëè-
òèé á³ëîê, ³ìóíîä³àãíîñòèêà.
Î. Á. Ãîðáàòþê, Î. Â. Îêóíåâ, Þ. Ñ. Íèêîëàåâ, Î. Â. Ñâÿòåíêî,
Â. À. Êîðäþì
Êîíñòðóèðîâàíèå, ñèíòåç, ôóíêöèîíàëüíàÿ õàðàêòåðèñòèêà
è ïðàêòè÷åñêîå ïðèìåíåíèå ñëèòîãî áåëêà SPA-ÂAPmut
Ðåçþìå
Öåëü. Ñîçäàíèå ãåííî-èíæåíåðíîãî ñëèòîãî áåëêà SPA-BAPmut è
eãî èñïîëüçîâàíèå êàê âòîðè÷íîãî èììóíîðåàãåíòà â èììóíîëîãè-
÷åñêèõ òåñòàõ.Ìåòîäû. Êëîíèðîâàíèå ãåíîâ, ÏËÐ, ñåêâåíèðîâà-
íèå ÄÍÊ, êóëüòèâèðîâàíèå áàêòåðèé, ýëåêòðîôîðåç, áèîñèíòåç è
î÷èñòêà áåëêîâ, ELISA, âåñòåðí-áëîò. Ðåçóëüòàòû. Ñ èñïîëüçî-
âàíèåì ïîñëåäîâàòåëüíîñòåé ÄÍÊ, êîäèðóþùèõ áåëîê À Staphylo-
coccus aureus (SPA) è áàêòåðèàëüíóþ ùåëî÷íóþ ôîñôàòàçó ñ óëó÷-
øåííûìè êàòàëèòè÷åñêèìè ñâîéñòâàìè (BAPmut), ñêîíñòðóèðî-
âàí ãåí ñëèòîãî áåëêà SPA-BAPmut è îáåñïå÷åíî åãî ïðåïàðàòèâ-
íîå ïîëó÷åíèå â ðàñòâîðèìîé ôîðìå âñëåäñòâèå ñèíòåçà â êëåò-
êàõ Escherichia coli. Îïðåäåëåíû óñëîâèÿ ôåðìåíòàöèè, ïðè êîòî-
ðûõ âûõîä SPA-ÂAPmut ñîñòàâëÿåò îêîëî 1 ã/ë êóëüòóðû E. coli. Ñ
ïðèìåíåíèåì ìåòîäà ìåòàëëîàôôèííîé õðîìàòîãðàôèè öåëåâîé
áåëîê ïîëó÷åí ñ ÷èñòîòîé áîëåå 95 %. SPA-ÂAPmut òåðìîñòàáè-
ëåí, à îáà åãî êîìïîíåíòà (SPA è ÂAPmut) ñîõðàíÿþò èììóíîãëîáó-
ëèíñâÿçûâàþùóþ è ôîñôàòàçíóþ àêòèâíîñòü íà ïðîòÿæåíèè äëè-
òåëüíîãî âðåìåíè. SPA-BAPmut ïîçâîëÿåò äåòåêòèðîâàòü 5 íã àí-
òèãåíà è 1 ìêã/ìë àíòèòåë. Âûâîäû. Ïîêàçàíà âîçìîæíîñòü ïðè-
ìåíåíèÿ SPA-ÂAPmut êàê óíèâåðñàëüíîãî âòîðè÷íîãî èììóíîðåà-
ãåíòà â èììóíîõèìè÷åñêèõ òåñòàõ.
Êëþ÷åâûå ñëîâà: áåëîê À, áàêòåðèàëüíàÿ ùåëî÷íàÿ ôîñôàòà-
çà, ñëèòûé áåëîê, èììóíîäèàãíîñòèêà.
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